{"title":"巴利替尼成功治疗两例粘膜受累的丘疹性荨麻疹病例","authors":"Tamás Malkovics, Orsolya N. Horváth, Miklós Sárdy","doi":"10.1002/jvc2.511","DOIUrl":null,"url":null,"abstract":"Both bullous pemphigoid and mucous membrane pemphigoid are autoimmune bullous diseases that can be challenging to treat in individual cases. Janus kinase inhibitors have shown efficacy in several autoimmune and inflammatory diseases, although these drugs are not yet widely used in autoimmune bullous diseases. We report two recalcitrant cases of pemphigoid with mucous membrane involvement which were successfully treated with the JAK 1/2 inhibitor baricitinib after all other feasible therapeutic options had been exhausted.","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":" February","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Two pemphigoid cases with mucous membrane involvement successfully treated with baricitinib\",\"authors\":\"Tamás Malkovics, Orsolya N. Horváth, Miklós Sárdy\",\"doi\":\"10.1002/jvc2.511\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Both bullous pemphigoid and mucous membrane pemphigoid are autoimmune bullous diseases that can be challenging to treat in individual cases. Janus kinase inhibitors have shown efficacy in several autoimmune and inflammatory diseases, although these drugs are not yet widely used in autoimmune bullous diseases. We report two recalcitrant cases of pemphigoid with mucous membrane involvement which were successfully treated with the JAK 1/2 inhibitor baricitinib after all other feasible therapeutic options had been exhausted.\",\"PeriodicalId\":94325,\"journal\":{\"name\":\"JEADV clinical practice\",\"volume\":\" February\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JEADV clinical practice\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.1002/jvc2.511\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JEADV clinical practice","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1002/jvc2.511","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Two pemphigoid cases with mucous membrane involvement successfully treated with baricitinib
Both bullous pemphigoid and mucous membrane pemphigoid are autoimmune bullous diseases that can be challenging to treat in individual cases. Janus kinase inhibitors have shown efficacy in several autoimmune and inflammatory diseases, although these drugs are not yet widely used in autoimmune bullous diseases. We report two recalcitrant cases of pemphigoid with mucous membrane involvement which were successfully treated with the JAK 1/2 inhibitor baricitinib after all other feasible therapeutic options had been exhausted.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
